TP53 and hepatocellular carcinoma: Moreover, etoposide combined with trichostatin A (a histone deacetylase inhibitor) overcame chemotherapy resistance in HBV-related hepatocellular carcinoma (HCC) cells via ERK inhibition and p53 activation (80).